Response to Liposomal Doxorubicin and Clinical Outcome of HIV-1–Infected Patients with Kaposi’s Sarcoma Receiving Highly Active Antiretroviral Therapy

REFERENCES

• Hogg R, O'Shaughnessy M, Gataric N, et al. Decline in deaths from AIDS due to new antiretrovirals. Lancet. 1997;349:1294.
   PubMed Web of Science ®Google Scholar
• Egger M, Hirschel B, Francioli P, et al. Impact of new antiretroviral combination therapies in HIV-infected pa-tients in Switzerland: Prospective multicenter study. Br Med J. 1997;315:1194–1195.
   PubMed Web of Science ®Google Scholar
• Palella F Jr, Delaney K, Moorman A, et al. Declining morbidity and mortality among patients with advanced HIV. N Engl J Med. 1998;338:853–860.
   PubMed Web of Science ®Google Scholar
• Jones J, Hanson D, Dworkin M, Jaffe H. Incidence and trends in Kaposi's sarcoma in the era of effective antiretroviral therapy. J Acquir Immune Defic Syndr. 2000;24:270–274.
   PubMed Web of Science ®Google Scholar
• Mihalcea A, Smith D, Monini P, Sgadari C, Ensoli B, Gill P. Treatment update for AIDS-related Kaposi's sarcoma. AIDS. 1999;13:5215–S225.
   Web of Science ®Google Scholar
• Krischer J, Rutschman O, Hirschel B, et al. Regression of Kaposi's sarcoma during therapy with HIV-1 protease in-hibitors: A prospective pilot study. J Am Acad DermatoL 1998;38:594–598.
   PubMed Web of Science ®Google Scholar
• Lebbe C, Blum L, Pellet C, et al. Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma. AIDS. 1998;12:F45–F49.
   PubMed Web of Science ®Google Scholar
• Benfield T, Kirk O, Elbrond B, Pedersen C. Complete histo-logical regression of Kaposi's sarcoma following treatment with protease inhibitors despite persistence of HHV-8 in lesions. Scand J Infect Dis. 1998;30:613–615.
   PubMed Web of Science ®Google Scholar
• Cattelan A, Calabro M, Averse S, et al. Regression of AIDS-related Kaposi's sarcoma following antiretroviral therapy with protease inhibitors: Biological correlates of clinical outcome. Eur J Cancer. 1999;35:1809–1815.
   PubMed Web of Science ®Google Scholar
• Niehues T, Horneff G, Megahed M, Schroten H, Wahn V. Complete regression of AIDS-related Kaposi's sarcoma in a child treated with highly active antiretroviral therapy. AIDS. 1999;13:1148–1149.
   PubMed Web of Science ®Google Scholar
• Shaw A, McLean K. Kaposi's sarcoma regression following treatment with a triple antiretroviral regimen containing nevirapine. Int J STD AIDS. 1999;10:417–418.
   PubMed Web of Science ®Google Scholar
• Dupin N, Rubin V, Gorin I, Calvez V, Pessis E. The influence of highly active antiretroviral therapy on AIDS-associated Kaposi's sarcoma. Br J DermatoL 1999;140:875–881.
   PubMed Web of Science ®Google Scholar
• Dupont C, Vasseur E, Beauchet A, et al. Long-term efficacy on Kaposi's sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients. AIDS. 2000;14:987–993.
   PubMed Web of Science ®Google Scholar
• Boiuin G, Gaudreau A, Routy J-P. Evaluation of the human herpesvirus 8 DNA load in blood and Kaposi's sarcoma skin lesions from AIDS patients on highly active antiretroviral therapy. AIDS. 2000;14:1907–1910.
   PubMed Web of Science ®Google Scholar
• Gill P, Wernz J, Scadden D, et al. Randomized phase III trial of liposomal daunorubicin (DaunoXome) versus doxorubi-cin, bleomycin, vincristine (ABV) in AIDS-related Kaposi's sarcoma. J Clin OncoL 1996;14:2353–2364.
   PubMed Web of Science ®Google Scholar
• Northfelt D, Dezube B, Thommes J, et al. Pegylated liposo-mal doxorubicin versus doxorubicin, bleomycin and vinc-ristine in the treatment of AIDS-related Kaposi's sarcoma: Results of a randomized phase III clinical trial. J Clin OncoL 1998;16:2445–2451.
   PubMed Web of Science ®Google Scholar
• Stewart S, Jablononski H, Goebel F, et al. Randomized comparative trial of pegylated liposomal doxorubicin ver-sus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. J Clin OncoL 1998;16:683–691.
   PubMed Web of Science ®Google Scholar
• Masood R, Husain S, Rahman A, et al. Potentiation of cytotoxicity of Kaposi's sarcoma related to immunodefi-ciency syndrome (AIDS) by liposome encapsulated doxo-rubicin. AIDS Res Hum RetroyiroL 1993;8:741–745.
   Web of Science ®Google Scholar
• Northfelt D, Martin F, Working P, et al. Pharmacokinetics, tumor localization, and safety of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi's sar-coma. J Clin PharmacoL 1996;366:55–63.
   Web of Science ®Google Scholar
• Gabizon A. Selective tumor localization and improved therapeutic index of anthracyclines in long circulating liposomas. Cancer Res. 199252: 891–896.
   Google Scholar
• Gill P, Espina B, Cabriales S, et al. A phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin (DaunoXome) in the treatment of advanced AIDS-related Kaposi's sarcoma. J Clin OncoL 1995;13:996–1003.
   PubMed Web of Science ®Google Scholar
• Northfelt D, Dezube B, Thommes J, et al. Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemo-therapy. J Clin OncoL 1997;15:653–659.
   PubMed Web of Science ®Google Scholar
• Krown S, Testa M, Huang J. AIDS-related Kaposi's sar-coma: Prospective validation of the AIDS Clinical Trials Group staging classification: AIDS Clinical Trials Group Oncology Committee. J Clin OncoL 1997;15:3085–3092.
   PubMed Web of Science ®Google Scholar
• Lock M, Griffiths P, Emery V. Development of a quantitative competitive polymerase chain reaction for human herpes-virus-8. J Virol Meth. 1997;64:19–26.
   PubMed Web of Science ®Google Scholar
• Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science. 1994;266:1865–1869.
   PubMed Web of Science ®Google Scholar
• AIDS Clinical Trials Group. Table of Grading Severity of Adult Adverse Experiences. Rockville, MD: Division of AIDS, National Institute of Allergy and Infectious Diseases; 1996.
   Google Scholar
• Núñez M, Machuca A, Soriano V, Podzamczer D, González-Lahoz J, and the Caelyx/KS Spanish Study Group. Clearance of human herpesvirus type 8 viraemia in HIV-1-positive patients with Kaposi's sarcoma treated with liposomal doxorubicin. AIDS. 2000;14:913–919.
   PubMed Web of Science ®Google Scholar
• Gill P, Rarick M, Bernstein-Singer M. Treatment of ad-vanced Kaposi's sarcoma using a combination of bleomycin and vincristine. Am J Clin OncoL 1990;13:315–319.
   PubMed Web of Science ®Google Scholar
• Gill P, Rarick M, McCutchan J, et al. Systemic treatment of AIDS-related Kaposi's sarcoma. Results of a randomized trial. Am J Med. 1991;19:427–433.
   Google Scholar
• Fischl M, Krown S, O-Boyle K, et al. Weekly doxorubicin in the treatment of patients with AIDS-related Kaposi's sar-coma. J Acquir Immun Defic Syndr. 1993;6:259–264.
   PubMed Web of Science ®Google Scholar
• Girard P-M, Bouchaud O, Goetschel A, et al. Phase ll study of liposomal encapsulated daunorubicin in the treatment of AIDS-associated mucocutaneous Kaposi's sarcoma. AIDS. 1996;10:753–757.
   PubMed Web of Science ®Google Scholar
• Newell M, Milliken S, Goldstein D, et al. A phase ll study of liposomal doxorubicin in the treatment of HIV-related Kaposi's sarcoma. Aust NZ J Med. 1998;28:777–783.
   PubMedGoogle Scholar
• Husak R, Mansmann U, Wolfer L-U, Geilen C, Goerdt S, Orfanos C. Kaposi's sarcoma is an important risk factor for survival in HIV-infected patients independent of CD4+ cell count. AIDS. 1999;13:432–433.
   PubMed Web of Science ®Google Scholar
• Uziely B, Jeffers S, Isacson R, et al. Liposomal doxorubi-cin: Antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol. 1995;13:1777–1785.
   PubMed Web of Science ®Google Scholar